biologic

Tenivac

Tetanus and Diphtheria Toxoids Adsorbed

Loss of exclusivityNovember 2015projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines Canada Ltd.

Drug detail

Brand nameTenivac
Active ingredientTetanus and Diphtheria Toxoids Adsorbed
Strength5LF,2LF/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalNovember 2003
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tenivac patent cliff — loss of exclusivity November 2015 | CliffBio